Drug Delivery Devices Market Set to Exceed US$ 450.7 Billion by 2035 as Biologic Revenue Surges Drive Urgent Expansion of Device Manufacturing Capacity Says Astute Analytica
View original at finance.yahoo.com“Broader market pressure is evident with Eli Lilly generating US$ 5.3 billion from Verzenio, straining parenteral lines.”
Lo que extrajimos de esta fuente
The claims Via News extracted from this document. We point to the source; we don't replace it.
SHL Medical has set a goal to produce 1.5 billion devices annually by 2025
80% confidenceSuch spending signals a permanent shift from outsourcing toward internalizing critical device production
80% confidenceThe global drug delivery devices market size was valued at US$212.6 billion in 2025 and is projected to reach US$450.7 billion by 2035, growing at a CAGR of 7.8% during the forecast period 2026-2035
80% confidenceThe drug delivery devices market has become the central pillar of pharmaceutical value creation
80% confidenceThe drug delivery devices market is entering a super-cycle fueled by an unprecedented convergence of chronic disease prevalence and biologic demand
80% confidenceInvestment magnitude in the drug delivery devices market has reached historic levels as companies race to secure capacity
80% confidenceThe market is surging due to the rising prevalence of chronic diseases and a massive shift toward home-based self-administration
80% confidenceEli Lilly's total manufacturing pledge reached over US$50 billion between 2020 and early 2025
80% confidence
Data points we hold from this source
| U.S. Food and Drug Administration · novel drug approvals | 61 approvals |
| U.S. Food and Drug Administration · first in class approvals | 24 approvals |
| U.S. Food and Drug Administration · breakthrough therapy approvals | 18 approvals |
| U.S. Food and Drug Administration · biosimilar approvals | 18 approvals |
| U.S. Food and Drug Administration · rare disease approvals | 26 approvals |
| U.S. Food and Drug Administration · priority review approvals | 28 approvals |
| U.S. Food and Drug Administration · fast track approvals | 22 approvals |
| U.S. Food and Drug Administration · first cycle approvals | 37 approvals |